StemCell Therapy

Sarasota Stem Cell Specialist Inject Knees for Bone on Bone as alliterative
http//:Geckojoiontandspine.com Using adipose and bone marrow stem cells combined as well as PRP or the growth factors from the blood she was able to avoid a knee replacement surgery for osteoarthr...

By: AskDoctorJL

See the original post here:
Sarasota Stem Cell Specialist Inject Knees for Bone on Bone as alliterative - Video

Bench to Bedside: Mesenchymal Stem Cells and ARDS, Part 1 - Carolyn Calfee
http://www.ibiology.org/ibioeducation/taking-courses/bench-to-bedside/mesenchymal-stem-cells-acute-respiratory-distress-syndrome.html In Part 1, Dr. Calfee begins by explaining that acute...

By: iBioEducation

Read the rest here:
Bench to Bedside: Mesenchymal Stem Cells and ARDS, Part 1 - Carolyn Calfee - Video

How long will it take to develop new therapies for kidney disease?
HSCI Kidney Program Leader Benjamin Humphreys, MD, PhD, at Brigham and Women #39;s Hospital answers patient frequently asked questions. (Video 3 of 4)

By: harvardstemcell

Read the original here:
How long will it take to develop new therapies for kidney disease? - Video

What is the link between diabetes and kidney disease?
HSCI Kidney Program Leader Benjamin Humphreys, MD, PhD, at Brigham and Women #39;s Hospital answers patient frequently asked questions. (Video 4 of 4)

By: harvardstemcell

Go here to read the rest:
What is the link between diabetes and kidney disease? - Video

Why stem cell therapy is not available in Europe or United States of America
In conversation with Dr Alok Sharma (MS, MCh.) Professor of Neurosurgery Head of Department, LTMG Hospital LTM Medical College, Sion, Mumbai. Explains, Why stem cell therapy is not available...

By: Neurogen Brain and Spine Institute

Here is the original post:
Why stem cell therapy is not available in Europe or United States of America - Video

After Stem Cell Therapy - Patient Interview
Patient Interview with #39;Josh #39; after stem cell treatment with Dr Mike Belich of Integrative Medical Clinics. The benefits of stem cell therapy and Regenerative Medicine.

By: Integrative Medical Clinics

View post:
After Stem Cell Therapy - Patient Interview - Video

A young paraplegic woman who underwent spinal stem cell therapy developed a growth in her back made up of nasal cells eight years later.

The team from the University of Iowa Hospitals and Clinics that removed and investigated the growth has reported the anomaly in a paper published in the Journal of Neurosurgery: Spine. Although the case is a rare occurrence (the first of its kind, that we know of) the authors admit this may simply be because patients that undergo therapy are not monitored long enough, and either way it provides ample evidence attesting to our lack of understanding around programming and controlling stem cell proliferation and differentiation post-transplant.

Human trials for this type of therapy are still at the very early stages, but animal trials have had some promising results. Several different types of cells have been experimented with for implantation including schwann cells (these surround nerves and sometimes grow on the spinal cord post-injury), foetal neural cells (with successes in rat studies) andnasal olfactory ensheathing cells (these are extracted from the lining of the nose and were the ones used in this particular case study).

The patient in question was just 18 years old when she suffered an injury during a car accident. She had been paraplegic for three years when she opted to undergo surgery, implanting olfactory mucosal cells into the injury site. These cells originate in the roof of the nasal cavity and have the ability to take on the characteristics of other cells in the body because they are partially made up of progenitor cells (adult stem cells). They also contain olfactory ensheathing cells, often used in spinal cord therapy trials. This is all despite, as the authors note, the fact that: "the ability of these cell types to differentiate into organised neural tissue in humans or support new neural growth in humans in the setting of spinal cord injury is unclear."

The location of the transplantation was not divulged in the Spine paper, but the New Scientist reports that it was carried out as part of an early stage trial in the Hospital de Egas Moniz in Lisbon, Portugal. In a paper, the Lisbon team revealed that out of 20 candidates, 11 regained some sensation and one person's paralysis actually worsened.

The woman's therapy did not flag up any issues at the time of implantation, but eight years down the line she complained of worsening back pain that had already been ongoing for a year. Scans at the University of Iowa Hospitals and Clinics revealed a mass, thick like mucus and surrounded by fibrous walls, on the spinal cord, at the site of the cell implantation. The investigators explain that the mass was made up "mostly of cysts lined by respiratory epithelium, submucosal glands with goblet cells, and intervening nerve twigs". Nasal elements were growing.

The mass was pressing against the spinal cord, causing the patient discomfort and threatening her spine. When it was extracted, the team could confirm it came from the neural stem-like cells implanted eight years earlier, because the cysts contained a network of non-functioning nerves that were separate from the spine (suggesting they were new) and bone.

"The presence of these nerves within the mass indicates the capacity of olfactory mucosa to support nerve fibre regeneration or new nerve formation," write the team.

In total, the mass was made up of two major parts, measuring 1.4 x 0.8 x 0.7 cm and 1.6 x 1.3 x 0.7 cm. When they were removed, the patient's pain immediately subsided.

These kinds of trials have been ongoing for years, but the fears have been that stem cells -- which have the ability to turn into any cell in the body if programmed to -- could just as easily mutate into something that is not intended, and create tumours in the long term.

See the original post here:
Stem cell therapy caused nasal tumour on paraplegic's back

PUBLIC RELEASE DATE:

8-Jul-2014

Contact: Jo Ann Eliason jaeliason@thejns.org 434-982-1209 Journal of Neurosurgery Publishing Group

Charlottesville, VA (July 8, 2014). A spinal mass was identified in a young woman with complete spinal cord injury 8 years after she had undergone implantation of olfactory mucosal cells in the hopes of regaining sensory and motor function. The case is reported and discussed in "Autograft-derived spinal cord mass following olfactory mucosal cell transplantation in a spinal cord injury patient. Case report," by Brian J. Dlouhy, MD, Olatilewa Awe, MD, Rajesh C. Rao, MD, Patricia A. Kirby, MD, and Patrick W. Hitchon, MD, published today online, ahead of print, in the Journal of Neurosurgery: Spine. The authors state that this is the first report of a spinal cord mass arising from spinal cord cell transplantation and neural stem cell therapy, and they caution that physicians should be vigilant in their follow-up of patients who undergo stem cell interventions.

In its natural state, the olfactory mucosa lines the roof of the nasal cavity, adjacent to the respiratory mucosa that lines the lower nasal cavity. In addition to smell receptor neurons, the olfactory mucosa contains progenitor cells (also known as adult stem cells) and olfactory ensheathing cellsboth of which have been shown to aid in the repair of the injured spinal cord in laboratory studies and in humans. The respiratory mucosa, on the other hand contains mucus-secreting goblet cells and mucus and serous fluidproducing cells.

The patient was 18 years old when she sustained a fracture dislocation at the 10th and 11th thoracic vertebral level in a motor vehicle accident. Despite surgery to stabilize the spine, the injury rendered the patient paraplegic. Three years later, in the hopes of regaining sensory and motor function in her lower limbs, the young woman underwent additional surgery at an institution outside the United States, during which an autograft of olfactory mucosa was placed in her spinal canal at the site of injury. Eight years after the experimental therapy, the woman sought medical care for mid- to lower-back pain at the University of Iowa Hospitals and Clinics. On neurological examination, she showed no sign of clinical improvement from the olfactory mucosal cell implantation, and imaging studies revealed a mass in her spinal canal pressing against the spinal cord. This mass was the source of the patient's pain.

Following surgery to remove the symptom-producing mass at the University of Iowa, a tissue analysis showed that the mass contained a small proportion of nonfunctional tiny nerve branches, whose appearance led the authors to suspect the nerve branches developed from transplanted neural stem-like cells. The tissue analysis also demonstrated that most of the mass consisted of multiple cysts lined with respiratory mucosa and underlying submucosal glands and goblet cells. Abundant mucus-like material was also found in the mass. Accumulation of this material over time produced the patient's symptoms.

The authors describe various ways of extracting olfactory mucosa cells for implantation. In this particular case, a portion of olfactory mucosa was transplanted; in other trials, olfactory ensheathing cells have been extracted from olfactory mucosa and purified prior to implantation. The authors suggest that the choice of bulk olfactory mucosa rather than purified olfactory ensheathing cells or stem cells as an autograft may lead to the development of a mass containing functional respiratory mucosal cells.

The authors point out that a rare case of spinal cord complication such as this should not discourage stem cell research and/or the transition of promising research to the clinical setting. However, the authors indicate the need for a better understanding of what can occur and urge clinicians to extend the monitoring period in patients treated with neural stem cell therapy for many years in case an adverse event such as this should arise. In summarizing the take-away message of the paper, Dr. Brian Dlouhy stated: "Exhaustive research on how transplanted cells divide, differentiate, and organize in animal models of disease, especially spinal cord injury, is critical to providing safe and effective treatments in humans."

###

Follow this link:
Spinal cord mass arising from neural stem cell therapy

A female patient in the US has grown a nose on her back following a failed experimental stem cell treatment that was intended to cure her paralysis. The nose-like growth, which was producing a thick mucus-like material, has recently been removed as it was pressing painfully on herspine. If you ever needed an example of the potential perils of stem cell therapy, and just how little we actually know about the function of stem cells, this is it. Its also notable that this stem cell therapy was carried out in a developed country, as part of an approved trial (apparently unwanted growths are more common in developing nations with less stringent medical safeguards).

Eight years ago, olfactory stem cells were taken from the patients nose and implanted in her spine. The stem cells were meant to turn into nerve cells that would help repair the womans spine, curing her of paralysis. Instead, it seems they decided to do what they were originally meant to do and attempt to build a nose. Over a number of years, the nose-like growth eventually became big enough and nosy enough to cause pain and discomfort to the patient. As reported by New Scientist, surgeons removed a 3-centimetre-long growth, which was found to be mainly nasal tissue, as well as bits of bone and tiny nerve branches that had not connected with the spinal nerves. [DOI: 10.3171/2014.5.SPINE13992 - "Autograft-derived spinal cord mass following olfactory mucosal cell transplantation in a spinal cord injury patient"]

Your olfactory system. 1 is the olfactory bulb (the bit of your brain that processes smells); 6 is the olfactory receptors that bind to specific chemicals (odors). [Image credit: Wikipedia]

What went wrong, then? Basically, at the top of your nasal passages there is the olfactory mucosa. This region contains all of the machinery for picking up odors, and the neurons for sending all of that data off to your brains olfactory bulb for processing. Cells from this region can be easily and safely harvested, and with the correct processing they behave just like pluripotent embryonic stem cells that can develop into many other cell types. These olfactory stem cells could develop into cartilage, or mucus glands, or neurons. The researchers obviously wanted the latter, to cure the patients spinal nerve damage but seemingly they got it wrong, and thus she sprouted a second nose. Moving forward, newer olfactory stem cell treatments have an isolation stage to prevent this kind of thing from happening. [Read:The first 3D-printed human stem cells.]

Its important to note that medicine, despite being carried out primarily on humans, is still ultimately a scientific endeavor that requires a large amount of trial and error. In the western world, its very, very hard to get a stem cell therapy approved for human trials without lots of animal testing. Even then, the therapies are often only used on people who have nothing to lose. Obviously its hard to stomach news like this, and Im sure that stem cell critics will be quick to decry the Frankensteinian abomination created by these scientists. But when you think about the alternative no advanced medicine and significantly reduced lifespans for billions of people then really, such experimental treatments are nothing to sneeze at.

Go here to see the original:
Woman grows a nose on her spine after experimental stem cell treatment goes awry

NEW YORK, July 7, 2014 /PRNewswire/ --Advanced Cell Technology, Inc. (OTCQB: ACTC) is a biotechnology company focused on developing and commercializing human pluripotent stem cell technology in the field of regenerative medicine. The company is currently conducting clinical trials for treating dry age-related macular degeneration (AMD) and Stargardt's macular degeneration (SMD), as well as several clinical and preclinical programs for other ocular therapies. Outside of ophthalmology, ACTC also has a preclinical development pipeline focused on autoimmune diseases, inflammatory diseases and wound healing. The company's intellectual property portfolio includes pluripotent human embryonic stem cells (hESCs), induced pluripotent stem cells (iPSCs), and other cell therapy research programs.

As the worldwide population has continued to age, so too has the need for regenerative medicine. In fact, by 2050, the number of people in the world over the age of 65 is expected to rise to 1.5 billion nearly triple the amount today. Unsurprisingly, as this demographic shift occurs over the next 35 years, health care expenditures are projected to increase rapidly as well. For example, in the US, the share of GDP devoted to healthcare is estimated to reach 34% by 2040 from about 18% just a few years ago. Considering the majority of treatments for chronic and/or life-threatening diseases that are available today only treat symptoms rather than offer a cure for the underlying cause, regenerative medicine such as the stem cell therapies being developed by ACTC are aimed at addressing this unmet and growing need.

Macular degeneration (i.e. age-related macular degeneration, or AMD) is a medical condition that results in a loss of vision in the center of the visual field (the macula) because of damage to the retina. This indication is the leading cause of blindness and visual impairment in adults over fifty years of age. Currently, it is estimated that there are approximately 30 million people worldwide who suffer from AMD ranging from early-stage to late-stage (i.e. legal blindness), with an estimated market size of around $30 billion. Further, in an article in the journal, Lancet projected that the number of people globally with AMD will be 196 million in 2020, growing to 288 million by 2040.

A full in-depth analyst report on ACTC that includes risk factors, industry review, financial position, potential revenues, review of current business model, competition breakdown, analyst summary, and recommendation can be viewed by using the following link at no cost:

http://bit.ly/-ACTC-AnalystReport

Copy and paste to browser may be required.

FORWARD-LOOKING DISCLAIMER

This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. Research report provided for informational purposes. This document, article or report is written and authored by Michael Maggi, Chartered Financial Analyst. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

Read the original here:
Advanced Cell Technology Analyst Report; Shareholder Value Likely to Continue to Erode for the Foreseeable Future by ...

What Goes Wrong in the Brain of a Child with Autism Spectrum Disorder ?
Dr. Nandini Gokulchandran from Neurogen Brain and Spine Institute explains what goes wrong in the brain of a child with Autism Spectrum Disorder? Stem Cell Therapy done at Dr Alok Sharma...

By: Neurogen Brain and Spine Institute

See the article here:
What Goes Wrong in the Brain of a Child with Autism Spectrum Disorder ? - Video

Stem Cell Therapy and Platelet Rich Plasma (PRP) Therapy

By: DR Kyle Kinmon

Continue reading here:
Stem Cell Therapy and Platelet Rich Plasma (PRP) Therapy - Video

Call A Stem.MD Health Advisor Now (561)2873018

Stem.MD

National Regenerative Medical Practice

Mets sign Bartolo Colon, 41, to a 2 year $20mm deal after being treated with the Stem MD proprietary BMAC procedure.

There was a time when, due to shoulder and elbow injueries, Colon, didn't know if he would ever pitch in the majors again.

Stem MDs foundation is built on the combined knowledge of the most trusted and effective sources and practitioners in regenerative medicine today. Leveraging our vast resources and collective experience, Stem MD offers a treatment plan tailored specifically to each patients needs. Our Health Consultants carefully assess your case and work with you and our doctors to ensure you get the treatment you deserve. We are committed to the best possible solution, which means knowing where breakthrough regenerative medicine can be used effectively, and only performing invasive surgery as a last resort. Read more about the Stem MD patient experience.

Dr. Joseph Purita is a pioneer within the worldwide orthopaedic surgery community. He has lectured on five continents and has been instrumental in helping some countries design their policies concerning the use of regenerative medicine. Dr. Purita graduated from Georgetown University Medical School and completed his residency at University of Miami-Jackson Memorial Hospital. Like all Stem.MD physicians, Dr. Purita prides himself on offering the latest surgical and non-surgical techniques to our clients, which range from celebrities to weekend athletes to the elderly. Read more about Stem MD.

In 2010, MLB player, Bartolo Colon received stem cell injections from Dr. Purita after half a decade struggle with shoulder and elbow injuries. Dr. Purita treated him and in a comeback that was nothing short of miraculous, Colon went on to pitch his signature 95-mile-an-hour fastball the next season.

Stem MDs foundation is built on the combined knowledge of the most trusted and effective sources and practitioners in regenerative medicine today. Leveraging our vast resources and collective experience, Stem MD is able to offer a treatment plan tailored specifically to each patients needs.

2.150 Bone Marrow Aspirate

Follow this link:
Stem Cell Therapy | Regenerative Medicine

Top 16 Safe Alzheimer Stem Cell Therapy Options Worldwide
The cure for Alzheimer #39;s has not yet been found, yet, the miraculous stem cells have been effective in treating the symptoms of the disease and re-establishing neural connections. Available...

By: placidways

Go here to see the original:
Top 16 Safe Alzheimer Stem Cell Therapy Options Worldwide - Video

What stem cell treatments (advertised elsewhere) can you recommend?
HSCI Kidney Program Leader Benjamin Humphreys, MD, PhD, at Brigham and Women #39;s Hospital answers patient frequently asked questions. (Video 2 of 4) More about stem cell tourism: http://www.closerlo...

By: harvardstemcell

Originally posted here:
What stem cell treatments (advertised elsewhere) can you recommend? - Video

July 5, 2014

redOrbit Staff & Wire Reports Your Universe Online

According to a new study appearing in the July 3 edition of the journal Cell Stem Cell, researchers from the Johns Hopkins University School of Medicine have uncovered a new genetic variant that could result in certain people having a predisposition to schizophrenia.

While there are many genetic variants that could increase the risk of developing a psychiatric disorder, they are insufficient to cause these diseases, the researchers explained. Now, however, the Johns Hopkins researchers have described a new strategy that could reveal how these so-called subthreshold genetic risks could impact the development of a persons nervous system by interacting with other risk factors.

This is an important step toward understanding what physically happens in the developing brain that puts people at risk of schizophrenia, senior author Dr. Guo-li Ming explained in a statement Thursday. Dr. Ming is a professor of neurology and neuroscience in the Johns Hopkins University School of Medicines Institute for Cell Engineering who worked on the study along with her husband, Dr. Hongjun Song.

In their study, Dr. Ming, Dr. Song and their colleagues explained that they used a multifaceted approach to find out why copy number variants in an area of the genome labeled 15q11.2 are prominent risk factors not just for schizophrenia, but for autism as well. Deletion of this part of a genome is associated with an increased risk of schizophrenia, but possessing extra copies results in an elevated risk of autism.

Their research focused on using a method which allows a patients skin cell to be reprogrammed into induced pluripotent stem cells (iPSCs), which can in turn be coaxed into creating any other type of cell. Using this technology, the study authors obtained stem cells from people with schizophrenia who were missing part of 15q11.2 on one of their chromosomes, ultimately coaxing them into neural progenitor cells, which are found in the developing brain.

By observing the process, the researchers found deficiencies during nerve development that could be linked to the gene CYFIP1, which maintains the structure of a nerve cell. By blocking the expression of this gene in developing mouse embryos, they found defects in the formation of the brains cerebral cortex, which plays a key role in consciousness.

The next step was to determine how this gene could interact with other factors, and they discovered that mutations in a pair of genes within a particular cellular pathway linked to CYFIP1 resulted in a significant increase in schizophrenia risk. According to the study authors, their research supports the belief that multiple factors in a single pathway could interact with one another to impact a patients potential risk for psychiatric disorders.

The reason, the team found, is that CYFIP1 plays a role in building the skeleton that gives shape to each cell, and its loss affects spots called adherens junctions where the skeletons of two neighboring cells connect, the university explained. A lack of CYFIP1 protein also caused some of the mice neurons to wind up in the brains wrong layer.

Visit link:
Johns Hopkins Researchers Locate Genetic Variant Associated With Schizophrenia

PUBLIC RELEASE DATE:

3-Jul-2014

Contact: Shawna Williams shawna@jhmi.edu 410-955-8236 Johns Hopkins Medicine

Johns Hopkins researchers have begun to connect the dots between a schizophrenia-linked genetic variation and its effect on the developing brain. As they report July 3 in the journal Cell Stem Cell, their experiments show that the loss of a particular gene alters the skeletons of developing brain cells, which in turn disrupts the orderly layers those cells would normally form.

"This is an important step toward understanding what physically happens in the developing brain that puts people at risk of schizophrenia," says Guo-li Ming, M.D., Ph.D., a professor of neurology and neuroscience in the Johns Hopkins University School of Medicine's Institute for Cell Engineering.

While no single genetic mutation is known to cause schizophrenia, so-called genomewide association studies have identified variations that are more common in people with the condition than in the general population. One of these is a missing piece from an area of the genome labeled 15q11.2. "While the deletion is linked to schizophrenia, having extra copies of this part of the genome raises the risk of autism," notes Ming.

For the new study, Ming's research group, along with that of her husband and collaborator, neurology and neuroscience professor Hongjun Song, Ph.D., used skin cells from people with schizophrenia who were missing part of 15q11.2 on one of their chromosomes. (Because everyone carries two copies of their genome, the patients each had an intact copy of 15q11.2 as well.)

The researchers grew the human skin cells in a dish and coaxed them to become induced pluripotent stem cells, and then to form neural progenitor cells, a kind of stem cell found in the developing brain.

"Normally, neural progenitors will form orderly rings when grown in a dish, but those with the deletion didn't," Ming says. To find out which of the four known genes in the missing piece of the genome were responsible for the change, the researchers engineered groups of progenitors that each produced less protein than normal from one of the suspect genes. The crucial ingredient in ring formation turned out to be a gene called CYFIP1.

The team then altered the genomes of neural progenitors in mouse embryos so that they made less of the protein created by CYFIP1. The brain cells of the fetal mice turned out to have similar defects in structure to those in the dish-grown human cells. The reason, the team found, is that CYFIP1 plays a role in building the skeleton that gives shape to each cell, and its loss affects spots called adherens junctions where the skeletons of two neighboring cells connect.

Originally posted here:
Schizophrenia-associated gene variation affects brain cell development

Scientists regenerate teeth using shark stem cells
Experimental procedure to correct tooth loss for accident victim Joe Howard results in tooth regeneration. Clip from documentary film Pandora #39;s Hope by Kit F...

By: Pandora #39;s Hope Movie

Here is the original post:
Scientists regenerate teeth using shark stem cells - Video

Embryonic Stem Cells their Controversy (unbiased view)
This video discusses what stem cells are and why their research is a divisive issue in today #39;s society. I use this video in my biology class at Beverly Hills...

By: Kyle Kobe

Read the original here:
Embryonic Stem Cells & their Controversy (unbiased view) - Video

A vote for stem cells
The $3 billion California Institute for Regenerative Medicine, the world #39;s largest stem cell research agency, is funded by the state - not the federal govern...

By: nature video

Here is the original post:
A vote for stem cells - Video